Abstract
The current landscape of cancer biomarkers is changing rapidly, with new and exciting developments. With the advances of proteomic technologies, many potential cancer biomarkers have been discovered. However, the number of new cancer biomarkers cleared or approved by the US FDA is rather limited. Although technological advances are important, clearly defining intended use, good study design and appropriate patient specimens are critical for the success of FDA approval. While obtaining FDA clearance/approval for newly developed and clinically useful cancer biomarkers has been slow, the reward for patient care could be enormous.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 135-136 |
| Number of pages | 2 |
| Journal | Expert Review of Proteomics |
| Volume | 11 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 2014 |
Bibliographical note
Funding Information:DW Chan has grant support from the National Cancer Institute (NCI) Early Detection and Research Network Reference Lab (BRL) and Clinical Proteomics Tumor Analysis Consortium (CPTAC). DW Chan is also one of the co-inventors of OVA1, which was licensed to Vermillion, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Keywords
- IVDMIA
- OVA1
- biomarker
- cancer
- proteomics
